Penumbra EPS - Earnings per Share 2014-2024 | PEN

Penumbra earnings per share (EPS) for the twelve months ending September 30, 2024 was $0.87, a 16.35% decline year-over-year.

  • Penumbra EPS for the quarter ending September 30, 2024 was $0.75, a 226.09% increase year-over-year.
  • Penumbra 2023 annual EPS was $2.32, a 4740% decline from 2022.
  • Penumbra 2022 annual EPS was $-0.05, a 135.71% decline from 2021.
  • Penumbra 2021 annual EPS was $0.14, a 131.82% decline from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.

Penumbra EPS - Earnings per Share 2014-2024 | PEN

  • Penumbra EPS for the quarter ending September 30, 2024 was $0.75, a 226.09% increase year-over-year.
  • Penumbra 2023 annual EPS was $2.32, a 4740% decline from 2022.
  • Penumbra 2022 annual EPS was $-0.05, a 135.71% decline from 2021.
  • Penumbra 2021 annual EPS was $0.14, a 131.82% decline from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$194.7B
Intuitive Surgical (ISRG)$191.9B
Alcon (ALC)$42.1B
Edwards Lifesciences (EW)$41.4B
IQVIA Holdings (IQV)$34.7B
IDEXX Laboratories (IDXX)$34.1B
DexCom (DXCM)$29.2B
STERIS (STE)$20.9B
Waters (WAT)$20.5B
SONOVA HOLDING (SONVY)$20.3B
Hologic (HOLX)$18.2B
Fresenius Medical Care AG KGaA (FMS)$13B
Sysmex ADR (SSMXY)$12.7B
Globus Medical (GMED)$11.3B
Teleflex (TFX)$9B
Masimo (MASI)$8.8B
Glaukos (GKOS)$8B
PROCEPT BioRobotics (PRCT)$4.9B
Integer Holdings (ITGR)$4.5B
Veracyte (VCYT)$3B
Inari Medical (NARI)$3B
LivaNova (LIVN)$2.8B
TransMedics (TMDX)$2.8B
Nihon Kohden (NHNKY)$2.3B
Elekta AB (EKTAY)$2.2B
Tandem Diabetes Care (TNDM)$1.8B
RxSight (RXST)$1.8B
Integra LifeSciences Holdings (IART)$1.8B
Alphatec Holdings (ATEC)$1.4B
Artivion (AORT)$1.1B